| Variable | Univariable Cox regression | Multivariable Cox regression using AR aberration and 3-lipid signature | Multivariable Cox regression using TP53 aberration and 3-lipid signature | Multivariable Cox regression using RB1 deletion and 3-lipid signature | Multivariable Cox regression using PI3K aberration and 3-lipid signature | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
Biomarker combinations | AR aberration and/or 3-lipid signature (Groups 1 and 2 vs 0) | 4.55 (2.27–9.12) | < 0.001 | 2.89 (1.39–6.00) | 0.005 | – | – | – | – | – | – |
TP53 aberration and/or 3-lipid signature (Groups 1 and 2 vs 0) | 5.22 (2.62–10.41) | < 0.001 | – | – | 3.26 (1.57–6.77) | 0.001 | – | – | – | – | |
RB1 deletion and/or 3-lipid signature (Groups 1 and 2 vs 0) | 3.05 (1.79–5.20) | < 0.001 | – | – | – | – | 1.98 (1.12–3.50) | 0.019 | – | – | |
PI3K aberration and 3-lipid signature (Group 2 vs 0 and 1) | 3.02 (1.75–5.21) | < 0.001 | – | – | – | – | – | – | 2.15 (1.21–3.82) | 0.009 | |
Clinicopatholgic factors | Albumin, g/La | 0.86 (0.82–0.91) | < 0.001 | 0.89 (0.84–0.95) | < 0.001 | 0.89 (0.84–0.95) | < 0.001 | 0.89 (0.84–0.95) | < 0.001 | 0.88 (0.83–0.94) | < 0.001 |
ECOG performance status (≥ 2 vs 0–1) | 3.94 (1.75–8.87) | < 0.001 | 1.74 (0.73–4.13) | 0.212 | 1.64 (0.69–3.91) | 0.263 | 1.72 (0.72–4.11) | 0.222 | 2.36 (0.98–5.67) | 0.054 | |
Pain at baseline (present vs absent) | 1.89 (1.12–3.19) | 0.018 | 1.73 (0.99–3.04) | 0.056 | 1.50 (0.86–2.63) | 0.152 | 1.77 (1.01–3.09) | 0.046 | 1.64 (0.93–2.90) | 0.089 | |
Haemoglobin (<90 g/L vs ≥ 90 g/L) | 2.70 (0.84–8.73) | 0.096 | – | – | – | – | – | – | – | – | |
PSA, ng/mLa | 1.00 (1.00–1.00) | 0.081 | – | – | – | – | – | – | – | – | |
ALP, IU/La | 1.00 (1.00–1.00) | 0.197 | – | – | – | – | – | – | – | – | |
Treatment type (taxane vs ARSI) | 1.05 (0.62–1.79) | 0.844 | – | – | – | – | – | – | – | – | |
Treatment line (second line vs first line) | 0.87 (0.51–1.48) | 0.597 | – | – | – | – | – | – | – | – | |
Visceral metastases (present vs absent) | 1.59 (0.75–3.37) | 0.225 | – | – | – | – | – | – | – | – | |
ctDNA Fraction | ctDNA fraction > 2% | 1.97 (1.06–3.66) | 0.032 | 1.74 (0.91–3.35) | 0.097 | 1.76 (0.93–3.33) | 0.083 | 2.22 (1.17–4.18) | 0.014 | 2.24 (1.18–4.24) | 0.014 |